(Q46578067)

English

The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma

scientific article published in December 2004

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15991268

The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15991268

0 references

1 reference

based on heuristic

inferred from title

author name string

Hatjiharissi E

1

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15991268

Terpos E

2

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15991268

Papaioannou M

3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15991268

Hatjileontis C

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15991268

Kaloutsi V

5

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15991268

Galaktidou G

6

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15991268

Gerotziafas G

7

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15991268

Christakis J

8

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15991268

Zervas K

9

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15991268

publication date

1 December 2004

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15991268

Hematological Oncology

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15991268

22

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15991268

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15991268

159-168

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15991268

Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology.

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

21 January 2018

Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Thalidomide for previously untreated indolent or smoldering multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone marrow angiogenesis in multiple myeloma: effect of therapy

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy.

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Thalidomide and dexamethasone combination for refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone marrow angiogenesis and circulating plasma cells in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression.

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of VEGF and its receptors by myeloma cells

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiogenesis-dependent diseases

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FHON.738

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HON.738

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15991268

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15991268

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46578067&oldid=2119103378"